Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
Addex Therapeutics Ltd., a Swiss biotechnology company, furnished this Form 6-K for September 2026. The filing reports that the company issued a press release dated September 25, 2026, which is filed as Exhibit 99.1. The text provided does not include the contents of that press release.
Financial and Operating Metrics
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash runway, clinical spending, or other financial metrics. It is not a periodic earnings report.
Material Changes Versus Prior Period
No specific financial, operational, clinical, corporate, or other material changes are described in the filing text provided. Any substantive information may be contained in Exhibit 99.1, which is referenced but not included.
Outlook, Risks, and Other Matters
- The company states that its business, financial condition, results of operations, and growth prospects face significant risks.
- The filing refers investors to the risk factors in the company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed May 15, 2026, and to other SEC filings.
- The filing contains the standard warning that forward-looking statements involve risks and uncertainties and that actual results may differ materially from expectations.
- Exhibit 99.1 is incorporated by reference into the company’s Form F-3 registration statement and Forms S-8 registration statements, to the extent not superseded by later filings.
Key Facts for Investors to Verify
- Obtain and review the September 25, 2026 press release filed as Exhibit 99.1.
- Determine whether the press release contains new clinical, regulatory, financing, strategic, or business information.
- Review the company’s Form 20-F for the year ended December 31, 2025 for financial condition, liquidity, risk factors, and available cash information.
- Assess the effect of the incorporation-by-reference provision on the company’s outstanding registration statements.